Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus PROLIXIN ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus PROLIXIN ENANTHATE.
CHLORPROMAZINE HYDROCHLORIDE INTENSOL vs PROLIXIN ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpromazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits antagonism at serotonin 5-HT2, histamine H1, alpha-1 adrenergic, and muscarinic receptors, contributing to its sedative, antiemetic, and hypotensive effects.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
Oral: 25-50 mg 2-3 times daily, up to 1000 mg/day in severe psychosis. IM: 25-50 mg every 1-4 hours until controlled, then switch to oral.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
None Documented
None Documented
15-30 hours; prolonged in elderly and hepatic impairment; active metabolites (e.g., 7-hydroxychlorpromazine) have longer half-lives (up to 12-24 hours)
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (~20-30%)
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Category C
Category C
Antipsychotic
Antipsychotic